name: Eylea Time-Based
version: '1.0'
created_date: '2025-06-16'
author: Luke Herbert with Claude Code
description: Eylea (aflibercept) protocol with time-based disease progression
model_type: time_based
transition_model: fortnightly
update_interval_days: 14
protocol_type: treat_and_extend
loading_dose_injections: 3
loading_dose_interval_days: 28
min_interval_days: 28
max_interval_days: 112
extension_days: 14
shortening_days: 14
disease_transitions_file: parameters/disease_transitions.yaml
treatment_effect_file: parameters/treatment_effect.yaml
vision_parameters_file: parameters/vision.yaml
discontinuation_parameters_file: parameters/discontinuation.yaml
demographics_parameters_file: parameters/demographics.yaml
baseline_vision_distribution:
  type: normal
  mean: 65
  std: 10
  min: 20
  max: 90
disease_transitions:
  NAIVE:
    NAIVE: 0.0
    STABLE: 0.3
    ACTIVE: 0.6
    HIGHLY_ACTIVE: 0.1
  STABLE:
    NAIVE: 0.0
    STABLE: 0.975
    ACTIVE: 0.025
    HIGHLY_ACTIVE: 0.0
  ACTIVE:
    NAIVE: 0.0
    STABLE: 0.05
    ACTIVE: 0.9
    HIGHLY_ACTIVE: 0.05
  HIGHLY_ACTIVE:
    NAIVE: 0.0
    STABLE: 0.01
    ACTIVE: 0.04
    HIGHLY_ACTIVE: 0.95
vision_change_model:
  naive_treated:
    mean: 0.0
    std: 1.0
  naive_untreated:
    mean: -1.0
    std: 1.0
  stable_treated:
    mean: 1.0
    std: 1.0
  stable_untreated:
    mean: -0.5
    std: 1.0
  active_treated:
    mean: -1.0
    std: 2.0
  active_untreated:
    mean: -3.0
    std: 2.0
  highly_active_treated:
    mean: -2.0
    std: 2.0
  highly_active_untreated:
    mean: -5.0
    std: 3.0
treatment_effect_on_transitions:
  STABLE:
    multipliers:
      STABLE: 1.1
      ACTIVE: 0.9
  ACTIVE:
    multipliers:
      STABLE: 2.0
      ACTIVE: 0.8
      HIGHLY_ACTIVE: 0.5
  HIGHLY_ACTIVE:
    multipliers:
      STABLE: 2.0
      ACTIVE: 1.5
      HIGHLY_ACTIVE: 0.75
discontinuation_rules:
  poor_vision_threshold: 20
  poor_vision_probability: 0.8
  high_injection_count: 50
  high_injection_probability: 0.02
  long_treatment_months: 60
  long_treatment_probability: 0.05
clinical_improvements:
  enabled: false
  use_loading_phase: true
  use_time_based_discontinuation: true
  use_response_based_vision: true
  use_baseline_distribution: false
  use_response_heterogeneity: true
  loading_phase_parameters:
    loading_injections: 3
    loading_interval_days: 28
  discontinuation_parameters:
    annual_probabilities:
      1: 0.125
      2: 0.15
      3: 0.12
      4: 0.08
      5: 0.075
  vision_response_parameters:
    loading:
      mean: 3.0
      std: 1.0
    year1:
      mean: 0.5
      std: 0.5
    year2:
      mean: 0.0
      std: 0.5
    year3plus:
      mean: -0.2
      std: 0.3
  response_types:
    good:
      probability: 0.3
      multiplier: 1.2
    average:
      probability: 0.5
      multiplier: 1.0
    poor:
      probability: 0.2
      multiplier: 0.6
